US Pharma MarketingAlphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model
If any proof was needed that big money is still available for AI drug development, look no further than the ten-figure series B hauled in by Isomorphic Labs. If any proof was needed that big money is still available for AI drug development, look no further than the 10-figure series B hauled in by Isomorphic Labs. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala…
If any proof was needed that big money is still available for AI drug development, look no further than the 10-figure series B hauled in by Isomorphic Labs.
Source: FierceBiotech